| Literature DB >> 33194871 |
Mauro Betelli1, Fabio De Stefano1, Alberto Tedeschi1.
Abstract
We describe the case of a patient hospitalized for the second time in a month due to delayed worsening of lung lesions in COVID-19 infection without bacterial superinfection. He was treated with hydroxychloroquine, IV dexamethasone and ruxolitinib with rapid improvement of respiratory failure; 1 month after the second discharge, maintaining low-dose oral prednisone, lung consolidations were significantly reduced on control CT. LEARNING POINTS: Modulation of immune over-response in late phases of COVID-19 can influence global outcome.Ruxolitinib and IV steroids can reverse the inflammatory process and lung lesions. © EFIM 2020.Entities:
Keywords: COVID-19; Janus kinase inhibitors; ruxolitinib
Year: 2020 PMID: 33194871 PMCID: PMC7655002 DOI: 10.12890/2020_001938
Source DB: PubMed Journal: Eur J Case Rep Intern Med ISSN: 2284-2594